By maintaining high-affinity binding and inducing prolonged activation of GLP-1R, dulaglutide effectively enhances insulin secretion, inhibits glucagon release, and delays gastric emptying—mechanisms critical for glycemic control in type 2 diabetes mellitus (T2DM) [43]. The gene discussed is INS; the disease is type 2 diabetes mellitus.